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Abstract
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Metabolic alterations in prostate cancer (PC) are associated with progression and aggressiveness.
However, the underlying mechanisms behind PC metabolic functions are unknown. Our group
recently reported on the important role of centromere protein F (CENPF), a protein associated
with the centromere-kinetochore complex and chromosomal segregation during mitosis, in PC
MRI visibility. In this study, we focused on discerning the role of CENPF in metabolic
perturbation in human PC3 cells. A series of bioinformatics analyses showed that CENPF is one
gene that is strongly associated with aggressive PC, and that its expression is positively correlated
with metastasis. By identifying and reconstructing the CENPF network, we found additional
associations with lipid regulation. Further untargeted metabolomics analysis using gas
chromatography-time-of-flight-mass spectrometry (GC-TOF-MS) revealed that silencing of
CENPF alters the global metabolic profiles of PC cells and inhibits cell proliferation, which
suggests that CENPF may be a critical regulator of PC metabolism. These findings provide useful
scientific insights that can be applied in future studies investigating potential targets for PC
treatment.
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INTRODUCTION
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Prostate cancer (PC) is the second most commonly diagnosed cancer and the fifth leading
cause of male mortality worldwide, with an estimated 1.3 million new cases and 359,000
associated deaths in 2018 [1, 2]. It is now widely accepted that proliferating cancer cells
alter their metabolic activities to satisfy increased needs for energy and biosynthetic
precursors, such as glucose [3]. Rather than utilizing the normal process of oxidative
phosphorylation, even with the presence of oxygen and fully functioning mitochondria,
these proliferating cancer cells favor aerobic glycolysis, which dramatic increases the uptake
of glucose and production of lactate; a process known as the Warburg Effect [4]. Glutamine
metabolism also plays a vital role in cancer cell energy metabolism by providing Krebs
cycle intermediates, which further corrobates the idea of altered cancer cell metabolism [5].
Most cancers depend on increased glutaminolysis to compensate for increased energy needs
and fill their carbon and nitrogen pools for the biosynthesis of macromolecules [6]. Besides
the higher utilization of the glycolytic pathway, cancer cells frequently exhibit a heightened
ability to synthesize lipids, and this increased lipogenesis is tightly coupled to glucose
metabolism [7, 8]. Reprogrammed energy metabolism is an important hallmark of the
upkeep of altered homeostasis in cancer [9]. For instance, increased glycolysis has been
observed in many cancer types, including PC [10, 11]. Several studies have shown that this
dysregulated metabolism plays a crucial role in PC progression [12–14]. These alterations in
metabolic features may represent potential prognostic biomarkers [15]. Therefore,
investigating PC metabolism could be an opportunity to find new prognostic or therapeutic
biological markers.

Author Manuscript

Metabolomics involves the study of metabolism and metabolite profiling, and is an
important analytical tool used in oncology for discovering novel biosignatures and
therapeutic targets [16]. It is widely applied as an interdisciplinary omics approach,
combining pattern recognition, bioinformatics, epidemiology, analytical biochemistry, and
biology [17]. This comprehensive analysis provides a valuable opportunity to better
understand the biochemical changes underlying cancer metabolism and improve early
detection, progression, and therapeutic monitoring [18]. Metabolomics can also respond to
clinical challenges by providing a method of detecting vital and promising novel biomarkers
[19, 20]. In terms of cancer, metabolomics can enable additional measurement of
downstream activities; thereby, allowing for the discovery of key oncometabolites [21].
These metabolites are markers of biochemical activity and are closely related to clinical
phenotypes [22]. An increasing number of metabolomic studies have focused on improving
the current understanding of PC. There have been several attempts at capturing metabolic PC
biomarkers due to evidence suggesting that perturbed metabolism may play a crucial role in
the development and progression of PC [14]. These metabolite profiles can be distinct and
could provide important prognostic information. For example, a metabolomic study of PC
and healthy controls found increased choline levels in malignant tissue [23]. PC can be a
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particularly attractive model for metabolic profiling; the healthy prostate has a unique
metabolism that is needed for producing prostatic fluid and alterations can be feasibly
tracked [24].
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Our group recently conducted a transcriptomic study on MRI-visible and invisible prostate
cancers to find differentially expressed genes (DEGs) between the two groups. We identified
centromere protein F (CENPF) as one of four genes related to MRI visibility, progressionfree survival, and metastatic deposits [25]. We further found that CENPF is a critical
regulator of cancer metabolism, potentially through pyruvate kinase M2 (PKM2). Our
findings align with previous reports suggesting that CENPF is a master regulator of
malignancy in PC [26, 27]. PKM2 is also well known to be a key player in PC metabolism
[28]; however, its link between CENPF and the development of PC using untargeted
metabolomics profiling has not been done before. By further defining the role of CENPF in
PC, we can gain a deeper mechanistic understanding of its effects in downstream events and
disease development.
This study aimed to determine the metabolic profile of CENPF-knockout (CENPFKO) PC
cells and identify differentially expressed metabolites (DEMs) that can used as prognostic
markers. Our experimental results showed that silencing of CENPF reduced global
metabolism. Additional computational analysis demonstrated that CENPF regulates PC
metabolism. Our results may allow us to derive new information that could be helpful in
better targeting the underlying mechanisms driving PC.

MATERIALS AND METHODS
Cell lines and culturing

Author Manuscript

Human PC3 cells were obtained from American Type Culture Collection (ATCC)
(Manassas, VA, USA). Cells were maintained in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and penicillinstreptomycin at 37°C with 95% air and 5% CO2. DMEM and FBS were purchased from
Life Technologies (Grand Island, NY, USA). Our CENPFKO PC3 cell line was constructed
using the CRISPR/Cas9 system by ALSTEM, LLC (Richmond, CA) and maintained as
described previously [29]. If frozen, after thawing, cells were used under 10 passages.
Mycoplasma contamination was monitored for periodically.
Identification of DEGs

Author Manuscript

We obtained the transcriptome of 1,321 PC patient samples from the Prostate Cancer
Transcriptome Atlas (PCTA; http://www.thepcta.org/), which was then used to develop our
Prostate Cancer Subtype (PCS) classification system [30]. PC transcriptome data was then
normalized and batch corrected by median-centering and quantile scaling (MCQ).
Independent PC data describing gene expression changes in multiparametric (MP)-MRIvisible and invisible tumors based on RNA sequencing (GSE95369) was obtained from the
Gene Expression Omnibus (GEO) database [31]. Read count data was normalized using the
TMM normalization method [32]. We then applied the integrated hypothesis testing method,
as previously reported [33]. Briefly, we performed three independent statistical tests,
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including the T-test, median ratio test, and rank-sum test, on each gene. To compute the
significance level (P-values) of the observed T-values, log2-median ratios, and rank-sum
differences, we used the empirical null hypothesis distribution, which was estimated by
random permutation of the samples. Finally, the adjusted P-values were computed using
Stouffer’s method. [34] DEGs between MRI visible and invisible patients in the MP-MRI
data were selected for if they had adjusted P-values < 0.05 and absolute fold-changes ≥ 2.
DEGs between mCRPC and primary patients in the PCTA were selected for if they had
adjusted P-values < 0.01 and absolute fold-changes ≥ 1.5. Functional enrichment analyses
were performed using gene set enrichment analysis (GSEA) for hallmark gene sets [35] and
DAVID (Ver. 6.8) [36].
Selection of CENPF network genes

Author Manuscript

To identify genes that are differentially regulated by CENPF in PC, we selected samples
from the PCTA data with high and low CENPF expression. High and low CENPF samples
were defined as those with upper and lower terciles of expression, respectively. We then
computed the adjusted P-values using the same method as described above. DEGs between
the high and low CENPF groups were selected for if they had adjusted P-values < 0.05.
Identification of hub genes in the CENPF network

Author Manuscript

To identify hub genes that could be potential regulator candidates of the CENPF network in
PC, we collected protein-protein interactions from 6 different databases; the Biological
General Repository for Interaction Datasets (BioGRID) [37]), the Databased of Interacting
Proteins (DIP [38]), High Confidence Protein-Protein Interactions (HitPredict) [39]), the
IntAct Molecular Interaction Database (IntAct) [40]), the Molecular INTeraction Database
(MINT) [12], and the Functional Protein Associations Network (STRING) [41]). We then
counted the number of interactions in the up and downregulated genes in the high and low
CENPF samples separately. Significance of the number of the interactions was computed as
enrichment P-values using Fisher’s exact test.
Reconstruction of a network model
To reconstruct a network model, we first selected for lipid metabolism and pathwayassociated genes from the CENPF network genes using Gene Ontology Biological Process
(GOBP). We then collected protein-protein interaction and transcription factor (TF)-target
interaction information of the differentially expressed lipid-related genes from the six
interactome databases that were used for our master regulator analysis. We also included
CENPF transcriptional target information from a prior study done by Aytes et al. [26]. The
network was visualized using Cytoscape (v. 3.2.1) [42].

Author Manuscript

Gas chromatography-time-of-flight-mass spectrometry (GC-TOF-MS) analysis
GC-TOF-MS analysis was performed on CENPFKO and control PC3 cells [43, 44]. Samples
were dissolved in 1 ml −20°C mixture of acetonitrile, isopropanol, and water (3:3:2 v/v) at a
pH of 7. The solution was then vortexed at 4°C for 5 min. Samples were centrifuged for 2
min at 14,000 rcf and 500 ul were aliquoted. The aliquots were then evaporated in a
Labconco Centrivap Cold Trap to complete dryness. The methoximation step was performed
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using a 10 ul solution of 40 mg/ml O-methylhydroxylamine hydrochloride (CAS:
[593-56-6]; Formula: CH5NO.HCl) and shaken for 90 min at 30°C. Then, 90 ul of Nmethyl-N-trimethylsilyltrifluoroacetamide (MSTFA) were added and the solution was
shaken for 30 min at 37°C. After, a 1 ul mixture of fatty acid methyl ester (FAME) retention
time markers were added. The mixture was transferred to amber crimp autosampler vials.
Measurements were done on a Leco Pegasus IV Time of Flight Mass Spectrometer coupled
to an Agilent 6890GC with an Agilent 6890 Split/Splitless Injector.

Author Manuscript

The column used was a Restek RTX-5Sil MS (95% dimethyl/5% diphenyl polysiloxane),
which has a 30 m length, 0.25 mm i.d., 0.25 um film thickness, and an additional 10 m guard
column. The injection volume used was 1 ul at 250°C. The GC parameters were set to have a
constant helium flow of 1 ml/min and an oven ramp temperature of 50°C (1 min hold) that
increases to 330°C at a rate of 20°C/min with a 5 min hold before cooldown. The transfer
line temperature was set to 280°C, and spectra were recorded in the electron ionization mode
at 70 eV with a filament temperature of 250°C TOF and scan range of 85–500 Da.
Annotation and identification of compounds

Author Manuscript

Detection or deconvolution of peaks and compounds was performed using the Leco
ChromaTOF software. Spectra were matched against the FiehnLib Mass Spectral and
Retention Index Library [23]. Post-curation and peak replacements were done using the inhouse developed BinBase software, which was set as follows: validity of chromatogram
(<10 peaks with intensities >107 counts/sec), unbiased retention index marker detection (MS
similarity >800, validity of intensity range for high m/z marker ions), and retention index
calculation by 5th order polynomial regression. Sample matrices with all known and
unknown compounds were then exported to a Microsoft excel sheet. A total of 490
compounds were detected. Of these, 200 were annotated as known compounds from
retention index and mass spectral matching, and the other 290 remained unknown.
Normalization and identification of DEMs
The raw data was normalized based on mTIC, which is the sum of all peak heights for all
identified metabolites for a sample [45]. The average mTIC was calculated and a
normalization factor for a sample was defined by dividing the average mTIC by the mTIC of
the individual sample. The normalized intensity was then calculated by multiplying the raw
intensity by the normalization factor. DEMs were selected according to the criteria of a FDR
adjusted P-value (q-value) ≤ 0.05 from a two-tailed Welch’s t-test and a fold-change ≥ 1.5
[46].
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The normalized intensities of the 524 metabolites were transformed into log2 scale and were
standardized as Z-score, and then principal component analysis (PCA) was applied to
understand variations in the metabolite profiles of different cell lines. Hierarchical clustering
of the DEMs was performed using Euclidean distance and ward linkage.
Metabolite enrichment analysis
Metabolites Biological Role (MBROLE) 2.0 was used to identify statistically significant
metabolic pathways enriched by the DEMs [47]. MBROLE is a web-based tool containing
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functional annotations on chemical compounds compiled from various public databases,
such as the Kyoto Encyclopedia of Genes and Genomes (KEGG) and PubChem. P-values
are computed based on hypergeometric distribution by comparing the number of metabolites
in the DEMs and background set, which is the annotated metabolites with KEGG compound
identifiers. Pathways with P-values < 0.1 and at least 2 DEMs were selected for functional
interpretation.
Proliferation assay
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Trypan blue assay was carried out to assess cell proliferation. Briefly, cells were seeded at a
density of 2×102 cells/well onto 6-well culture plates in complete medium. Following 24 hrs
of cell growth, each well culture was maintained and incubated for 2 days. The medium was
replaced every day. After 48 hrs, cells were trypsinized, washed, and resuspended in PBS
containing 0.4% trypan blue. The number of viable cells were counted using a
hemocytometer, as per standard protocol. Each experiment was done a minimum of three
independent times. The results are presented as the percentage of viable cells relative to that
of the control.
Branched-chain amino acid/aromatic amino acid (BCAA/AAA ratio)
The BCAA/AAA ratio was calculated as the ratio between the concentration of BCAAs
(valine, leucine, and isoleucine) and AAAs (phenylalanine and tyrosine) [48].

BCAA / AAA ratio =

[ valine ] + [ leucine ] + [ isoleucine ]
[ phenylalanine ] + [ tyrosine ]

Author Manuscript

The concentration of each amino acid was calculated by dividing the quantified intensity by
the quantified m/z.
Acetate measurement assay
Acetate levels were measured using an Acetate Colorimetric Assay Kit (Biovision Inc.)
according to the instructions provided. Briefly, cells (1 × 106) were rapidly homogenized
with 100 μl of ice-cold acetate assay buffer for 10 min on ice. The mixture was then
centrifuged at 12000 rpm for 5 min and the resulting supernatant was collected. After, 1–50
μl of sample (50–200 μg) were added onto a 96-well plate. The final volumes were adjusted
to 50 μl with acetate assay buffer. The reaction was incubated at room temperature for 40
min and optical reading was taken at 450 nm using spectrophotometer. The unknown sample
concentration was calculated from the standard curve.

Author Manuscript

Statistical analysi
Results were expressed as mean ± SE from at least three independent experiments. To
evaluate differences between two groups, statistical analysis was done using Student’s t-test.
Unless otherwise indicated, P < 0.05 was deemed significant. We used MATLAB (v.9.0;
Mathworks, Natick, MA, USA) and R (v.3.5) for bioinformatic analyses.
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RESULTS
Transcriptome analysis reveals genes associated with aggressive PC
To identify genes associated with aggressive PC, we utilized two independent transcriptome
datasets. One was obtained from the PCTA database, which provided 1,321 PC
transcriptome profiles [30] (hereafter referred to as PCTA). The other was from a separate
study that examined the gene expression differences between MP-MRI-visible and invisible
tumors [25] (hereafter referred to as MRI). The transcriptome data was produced using RNA
sequencing, and the count data was deposited in the GEO database under the accession
number GSE95369. Of note, survival analysis of these independent study cohorts presented
4 gene signatures as being significantly correlated with metastatic progression and
biochemical recurrence.
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With this transcriptome data, we hypothesized that DEGs between metastatic castrationresistant PC (mCRPC) versus primary PC and MP-MRI-visible versus invisible tumors may
be potential regulator candidates of PC progression. We then performed integrative
hypothesis testing of the PCTA and MRI datasets to identify 182 (mCRPC vs. PC) and 457
(MRI-visible vs. invisible) DEGs (Figure 1A; see Methods for details). Between these two
compared groups, 10 shared DEGs were identified (Figure 1B). SPP1 (secreted
phosphoprotein 1), CENPF, MEX3A (mex-3 RNA binding family member A), NUSAP1
(nucleolar and spindle associated protein 1), and TOP2A (DNA topoisomerase II alpha)
were significantly upregulated in mCRPC and MRI-visible PC, while GAS1 (growth arrest
specific 1), PGM5 (phosphoglucomutase 5), CHRDL1 (chordin like 1), PCAT4 (prostate
cancer associated transcript 4), and H19 (H19, imprinted maternally expressed transcript)
were significantly downregulated. Interestingly, the clinical significance of CENPF in PC
was previously reported [49] and identified as a potential master node of PC malignancy
[26].
CENPF expression is correlated with PC progression

Author Manuscript

We examined CENPF expression in tissues with 5 distinct disease statuses (benign, Gleason
score (GS)<6, GS=7, GS>7, and mCRPC) to discern the association of CENPF with disease
progression (Figure 2A). Consistent with previous studies [27], CENPF gene expression
levels increased significantly in higher GS and mCRPC tissue (one-way ANOVA P < 0.001,
rank-sum P < 0.001). A prior cross-species study [27] and MRI study [25] revealed a
regulatory relationship between CENPF and FOXM1 in PC progression. We thus checked
for a correlation between CENPF and FOXM1 expression in the PCTA data [30]. We found
that expression of CENPF and FOXM1 exhibited a significant positive correlation in all
PCTA samples and individual disease states (Figure 2B). This implies that gene expression
and regulation of CENPF and FOXM1 are significantly associated with PC progression.
Genes involved in the CENPF network in PC
Given the significance of CENPF expression in PC progression, investigating the
downstream CENPF transcriptional network may be relevant in discovering the molecular
mechanisms of PC. For this, we defined high and low CENPF-expressing groups in the
PCTA by selecting for upper and lower terciles. Secondly, we identified significantly up and
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downregulated CENPF-associated genes in the high and low groups (Figure 3A). To identify
molecular pathways and cellular processes regulated by CENPF, we then performed GSEA
and functional enrichment analysis using hallmark genesets from MsigDB and GOBP.
GSEA results showed that the E2F target, G2M checkpoint, MYC target, and mitotic spindle
gene sets were significantly enriched for in the high CENPF group. However, myogenesis,
TGF-beta signaling, UV response, protein secretion, apical surface, apoptosis, epithelialmesenchymal transition (EMT), apical junction, and hypoxia gene sets were significantly
enriched for in the low CENPF group (Figure 3B).

Author Manuscript

Functional enrichment analysis results from DAVID also showed consistent results with
GSEA. Cell cycle-related GOBPs, like mitosis, nuclear division, organelle fission, and
chromosome segregation, were enriched for in the high CENPF group. This may be
reflective of the known function of CENPF as a core member of the centromere-kinetochore
complex. Development-related (cell development, muscle system processes, muscle
structure development), motility-related (regulation of cell migration, locomotion, and
motility), and response to stimuli-related GOBPs (response to wounding and chemical
stimuli) were enriched for in the low CENPF group (Figure 3C). In addition to this, we
searched for hub genes among the identified DEGs that could be key regulators of the
CENPF downstream transcriptional network (see Methods for details).
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When searching for both up and downregulated genes among the DEGs, MYC, CCDC8
(Coiled-Coil Domain-Containing Protein 8), BRCA1, CDK1 (Cyclin Dependent Kinase 1),
and PLK1 (Polo-like kinase 1) were found to be the top 5 genes that act as key regulator
candidates in the CENPF network (Figure 3D). When performing the same analysis with
only upregulated genes, these 5 genes were selected for with significant consistence (Figure
3E). When searching for only downregulated genes, SMAD3 (SMAD Family Member 3),
GSK3B (Glycogen Synthase Kinase 3 Beta), CAV1 (Caveolin 1), SMAD4 (SMAD Family
Member 4), and PRKCA (Protein Kinase C Alpha) were identified as the top 5 regulator
candidates (Figure 3F).
CENPF and lipid regulation
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Lipid-related GOBPs, including positive regulation of lipid biosynthetic process, regulation
of lipid metabolic process, phospholipid scrambling, lipid modification, lipid metabolic
process, cellular lipid metabolic process, lipid biosynthetic process, cellular response to
lipid, and response to lipid, were highly enriched for by the downregulated genes in high
CENPF samples (Figure 4A). To identify genes that both regulate lipid-related functions and
are CENPF-dependent, we performed hub gene analysis on those listed to be involved in
lipid-related GOBPs in Figure 4A, which resulted in BRCA1, SMAD3, CAV1, GSK3B, and
NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1) (P < 0.05) (Figure 4B). We
then reconstructed a network model describing the interactions between the presence of
CENPF and lipid-related genes (Figure 4C).
CENPFKO cells show perturbed cellular metabolism and metabolic pathways
To elucidate on the metabolite enrichment analysis between control PC3 and CENPFKO
cells, the annotated DEPs were further explored for their corresponding biological meaning
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by gene ontology annotations retrieved from the Gene Ontology Consortium and mapped
against their KEGG biological pathway information. A total of 524 metabolites were
profiled and quantified from the GC-MS-based metabolomics experiment. The intensities of
the 524 metabolites were normalized based on mTIC. The normalized data was then
sequentially log2 and z-score transformed before PCA, which revealed a difference in
overall metabolite expression profiles between the control and CENPFKO cells (Figure 5A).
Further statistical significance analysis between the two cell lines identified a total of 92
DEMs. Of these 92 DEMs, 68 were upregulated and 24 were downregulated in CENPFKO
cells, compared to controls. These metabolites were determined based on a fold-change ≥
1.5 and a FDR adjusted P-value (q-value) ≤ 0.05 (Figure 5B). Among the 92 DEMs, 23
upregulated and 12 downregulated metabolites in CENPFKO cells were annotated with a
KEGG compound identifier (Figure 5C). The expression profiles of the 92 DEMs were
illustrated in a heatmap (Figure 5D).
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The annotated metabolites were labeled with the corresponding compound names.
Functional enrichment analysis of the annotated DEMs based on KEGG pathways identified
various dysregulated metabolic pathways in CENPFKO cells (Table 1). Upregulated
metabolites were enriched for pathways related to carbon fixation, vitamin B6 metabolism,
pyruvate metabolism, pentose phosphate pathway, phosphotransferase, purine metabolism,
and zeatin biosynthesis. Downregulated metabolites were primarily enriched for pathways
related to amino acid biosynthesis and metabolism (Table 1).
CENPF stimulated PC proliferation
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To determine whether CENPF is also required for regular cell growth. Our cell proliferation
assay compared growth between CENPFKO and control cells. The proliferation rate of
CENPFKO cells was significantly reduced after 48 hrs (Figure 6A). We speculated that
CENPF is required for regulating acetate metabolism. As expected, our results showed that
acetate levels in CENPFKO cells were almost completely reduced (Figure 6B). Several
studies have demonstrated that significant alterations are found in the utilization of BCAAs
in cancers [50]. We then check BCAA/AAA ratio from metabolomics data. In contrast to the
control, BCAA/AAA ratio was significantly decreased (Figure 6C).

DISCUSSION
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The aim of this study was to determine the role of CENPF in tumor growth and aggression
in both clinical PC tissue and human PC3 cells. Although CENPF is named after its
association with the centromere-kinetochore protein complex, it has been reported to
function in mitosis regulation and cellular proliferation as well [51–53]. Previous studies
have also shown that CENPF can potentially predict PC clinical outcome and progression
[49]. We decided to investigate if CENPF expression could stratify risk in PC patients, and if
there are any resulting perturbed metabolite panels that can be used as a prognostic
signature. Our study found that CENPF expression is necessary for cellular growth.
Silencing of the gene resulted in significantly delayed proliferation. Furthermore, we found
that increased CENPF expression may be correlated with PC aggressiveness. PC tissue with
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higher clinical grades showed increased expression of CENPF, which further validates the
potential use of CENPF as a prognostic marker of PC progression.
Our current study also focused on the relationship of CENPF to other genes as well. Prior
studies have suggested that CENPF and FOXM1 may have a synergistic interaction that
drives PC malignancy and aggressiveness [26, 54]. In addition, our previous study found that
ALDH2 may be negatively correlated to CENPF [25]. In order to validate these relationships
in the context of predicting PC aggressiveness, we tested these genes in clinically graded PC
samples. We found that PC samples with PAM50 scores > 7 had higher CENPF expression
and, consequently, increased FOXM1 and reduced ALDH2 levels (Supplementary Figure 1).
This confirmed our initial speculation on the relationship of CENPF to these other genes.
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To further examine the association of CENPF with various PC types, we tested for the
expression of CENPF in PC tissue classified with our PCS signatures. Our prior analysis of
subtype-specific gene expression patterns found that PCS1 and PCS2 tumors reflect luminal
subtypes, while PCS3 tumors are basal [30]. We found that PCS1 and PCS2 tissues had
significantly higher expression of CENPF, which suggests that CENPF is elevated in luminal
subtypes (Supplementary Figure 2). Additionally, this could mean that testing for both
CENPF expression and our PCS signature could potentially identity which PC tissues are
luminal. Considering how luminal subtypes are transformation-competent and, thereby,
more progressive and aggressive, it would be clinically helpful to be able to accurately
identify tissue subtypes.
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In this study, we found that CENPF and its network may be controlling PC aggression and
progression by altering cellular metabolism. BCAA metabolism is one such pathway that is
regulated by CENPF, and there have been several conflicting studies regarding the
relationship between BCAA metabolism and cancer progression. Loss of BCAA catabolism
has been shown to lead to BCAA accumulation and activation of mTORC1 in liver and
ovarian cancers [55–57]. However, contrastingly, loss of BCAA catabolism was found to
limit proliferation in glioblastoma, NSCLC, and breast cancer[58–60]. As described recently
by White et al. [61], BCAAs are also currently used as biomarker for disease pathogenesis.
They have been shown to significantly involved in the development of different diseases,
such as type 2 diabetes (T2D) and cardiovascular problems. Our own study found that
elevated CENPF expression enhances BCAA catabolism, which leads to increased PC cell
proliferation and tumor formation. Furthermore, we found that low grade PC has limited
BCAA catabolism, and this accumulation of BCAAs had no effect on mTORC1. The
observed changes in CENPF-dependent acetate concentration also support the regulation of
BCAA catabolism. Acetate is one of the major short-chain fatty acids (SCFAs) and is a key
substrate for cancer bioenergetics[62]. Fatty acid synthesis requires acetate and acyl-CoA
synthetase short chain family member 2 (ACSS2) [63]. Given acetate derived from glucose
metabolism rewiring is elevated in cancer cells[64], it has now become apparent that acetate
metabolism regulates many different types of cancer through its role in energy or lipid
production. Additionally, acetate can also affect certain cancers through regulation of histone
acetylation [65].
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These findings provide a basis for further studies. Despite this exciting discovery, the main
limitation of our study was the lack of a large prospective patient cohort to test on.
Additionally, the functional mechanisms behind CENPF that are responsible for these effects
in PC patients remain elusive. However, given our previous observations [25, 29] and current
human PC data bioinformatic analyses, future studies could be expanded to investigate the
molecular mechanisms associated with CENPF and assess whether CENPF silencing can be
a clinical biomarker for diagnosing PC or predicting aggressiveness.
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Refer to Web version on PubMed Central for supplementary material.
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Significance Statement
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Prostate cancer (PC) remains to be a worldwide public health concern. It has been
accepted that proliferating PC cells satisfy elevated energy requirements needed to
support accelerated cell division by modulating metabolism. However, the mechanisms
behind these metabolic alterations are largely unknown. One key modulator that has been
previously identified is centromere protein F (CENPF), which is shown to be upregulated
in PC cells. Despite this knowledge, there has been no detailed systematic analysis on
how CENPF regulates PC cellular metabolism. In this study, we aimed to better
understand the global metabolic changes mediated by CENPF in PC cells using a
quantitative metabolomics approach, which includes gas chromatography-time-of-flightmass spectrometry (GC-TOF-MS). The metabolites and metabolic enzymes that we
identified may serve as potential biomarkers or therapeutic targets. These findings shed
new light on the biochemical mechanisms and biological functions of CENPF in PC and
may pave the way for novel treatment options.
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Figure 1. Selection of genes associated with aggressive PC.
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(A) Venn diagram depicts the number of DEGs in MP-MRI-visible vs. invisible tumors and
mCRPC vs. primary PC. Transcriptome data of MP-MRI visibility was obtained from the
GEO database (GSE95369) and mCRPC and PC gene expression profiles are from PCTA.
DEGs for MRI visibility were selected for if they had an adjusted P-value < 0.05 and foldchange ≥ 2. DEGs in the mCRPC and PC group were selected for if they had an adjusted Pvalue < 0.01 and fold-change ≥ 1.5. (B) List of overlapping genes associated with both MRI
visibility and metastatic progression.
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Figure 2. Gene expression of CENPF in PC progression.
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(A) Lollipop plot (upper panel), box plot (lower left), and line plot (lower right) display
CENPF gene expression patterns across disease progression from the PCTA data. Lollipop
plot shows CENPF expression levels of individual samples. For each disease state, samples
were sorted by CENPF expression. Whiskers on the box plot indicate interquartile range
(IQR) and 1.5 times the IQR. Individual dots on the box plot represent individual samples.
The line plot shows the average expression level of CENPF for each disease state. Dotted
lines on the plot indicate the trend of gene expression between disease states. (B) Scatter
plot and regression lines were drawn to illustrate correlation between CENPF and FOXM1
in all the PCTA samples and each disease state.
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Figure 3. Identification of genes in the CENPF network.
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(A) Heatmap depicts differential expression patterns of the genes between samples with high
and low CENPF expression. Red and blue indicate up- and downregulated genes,
respectively, in PC samples with high CENPF expression (CENPF high) compared those
with low expression (CENPF low). (B) Bar plot displays enrichment scores of hallmark gene
sets based on GSEA. All the gene sets on the plot were significantly enriched for in the
CENPF-high or low groups with nominal P-value < 0.05. NES; normalized enrichment
score. (C) Gene Ontology Biological Processes (GOBPs) enriched for by DEGs in CENPFhigh versus CENPF-low with P-value < 0.05. (D-F) Scatter plots illustrate up- and
downregulated genes in the CENPF network (D), upregulated gene in the CENPF network
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(E), and downregulated genes in the CENPF network (F). Hub genes are indicated with red
dots. These genes have more than 3 interactions in the CENPF network and P-values < 0.05.
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Figure 4. Association of the CENPF network with lipid regulation.

(A) Bar plot shows enrichment scores of the GOBPs associated with lipid metabolism and
pathways in the DEGs of CENPF-high versus CENPF-low. (B) Scatter plot illustrates the
number of interactions among the lipid metabolism and pathway-associated genes in the
CENPF network. Genes represented by red dots indicate hub genes with P-values < 0.05.
(C) A network model describing interactions among the lipid-associated genes in the
CENPF network. Node color represents up- and downregulation in CENPF-high versus low
PCs. Edges represent interactions.

Author Manuscript
Proteomics. Author manuscript; available in PMC 2020 June 01.

Shahid et al.

Page 22

Author Manuscript
Author Manuscript
Author Manuscript
Figure 5. Metabolomic profiling of CENPFKO PC3 cells.
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(A) Principal component analysis (PCA) plot based on the 524 metabolites profiled as
different between CENPFKO and control PC3 cells. (B) Volcano plot displaying the
statistical significance (log10-based P-value) and magnitude of the changes (log2-based foldchange) of the metabolites. Red and cyan indicate statistically significant up- and
downregulation in CENPFKO cells, respectively (fold-change ≥ 1.5 and FDR adjusted Pvalue (q-value) ≤ 0.05). (C) The number of DEMs identified from the statistical analyses are
summarized. (D) The heatmap shows the expression profiles of the 92 DEMs. The 37
annotated DEMs with compound names were marked with the corresponding identifications.

Proteomics. Author manuscript; available in PMC 2020 June 01.

Shahid et al.

Page 23

Author Manuscript
Author Manuscript
Author Manuscript
Figure 6. Perturbed metabolisms due to CENPF silencing.
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(A) Cell growth analysis using trypan blue staining. Cell proliferation was suppressed in
CENPFKO cells compared to controls at 48 hrs. *P<0.05 (two-sided Student’s t-test). (B)
CENPFKO cells showed decreased synthesis of acetate compared to control. (C) Box plot
showing BCAA/AAA ratio in Ctrl and CENPFKO cells. CENPFKO cells showed inhibited
BCAA content compared to Ctrl. *P<0.05 and **P<0.01 (two-sided Student’s t-test). Error
bars represent standard deviation (n=3).
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Pathways significantly enriched for by the DEMs.
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KEGG patdway

Count

p-value

FDR

Metabolites

Carbon fixation in photosynthetic
organisms

4

0.0099

0.3510

ribulose-5-phosphate, ribose-5-phospahte, pyruvic acid,
phosphoenolpyruvate

Vitamin B6 metabolism

3

0.0108

0.3510

Ribulose-5-phosphate, pyruvic acid, pyridoxal-5phospahte

Pyruvate metabolism

2

0.0218

0.3770

pyruvic acid, phosphoenolpyruvate

Pentose phosphate pathway

4

0.0290

0.3770

ribulose-5-phosphate, ribose-5-phospahte, pyruvic acid,
gluconic acid lactone

Phosphotransferase system (PTS)

4

0.0290

0.3770

pyruvic acid, phosphoenolpyruvate, mannose, hexitol

Purine metabolism

4

0.0436

0.4720

ribose-5-phospahte, inosine 5’-monophospahte,
adenosine-5- monophosphate, adenine

Zeatin biosynthesis

2

0.0594

0.5450

adenosine-5- monophosphate, adenine

Amino-tRNA biosynthesis

6

0.0038

0.1570

valine, threonine, methionine, isoleucine, glutamine,
alanine

Valine, leucine and isoleucine biosynthesis

3

0.0071

0.1570

valine, threonine, isoleucine

Glucosinolate biosynthesis

3

0.0221

0.2930

valine, threonine, isoleucine

Valine, leucine and isoleucine degradation

2

0.0266

0.2930

Valine, isoleucine

Cysteine and methionine metabolism

3

0.0470

0.4140

methionine sulfoxide, methionine, alanine

ABC transporter

5

0.0642

0.4710

valine, threonine, isoleucine, glutamine, alanine

Up

Down
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